NCT06455319
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 5 more changesShow less
- Eligibility criteria expanded, about 98 words
- Interventions modified
- Trial arms changed: 3 → 2
- Study description expanded, about 39 words
- Publications: details revised at 4 of 4 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Primary completion date: Oct 2028 to Nov 2028
- Start date changed from estimate of Oct 2025 to Nov 12, 2025
- Notable Start date: Jul 2025 to Oct 2025
- Primary completion date: Jul 2028 to Oct 2028
- Study completion date: Jul 2030 to Aug 2030
- Notable Start date: Apr 2025 to Jul 2025
- Primary completion date: Apr 2028 to Jul 2028
- Study completion date: Apr 2030 to Jul 2030
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
AUC C-peptide between ATG responder and non-responder arms
Timeframe: 12 Months
Change in 2-hr MMTT AUC C-peptide
Timeframe: 6 months
Secondary (1)
Immune and beta cell mechanistic analyses
Arms and interventions
Anti-thymocyte globulin (ATG) intravenous infusionExperimental
ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
verapamil extended release capsuleExperimental
Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
Drugs: Anti-thymocyte globulin (ATG), verapamil extended release capsule
Sites
2 sites in 1 country